WID-easy

The WID®-easy test is an epigenetic DNA methylation test developed to detect all carcinomas originating from the uterus, particularly endometrial carcinoma and endocervical carcinoma. This test is indicated for peri- and postmenopausal women with abnormal vaginal bleeding and the sample is taken by cervicovaginal swab. The test has a 95% lower rate of false-positive results than transvaginal ultrasound. Using the test, the number of women requiring a hysteroscopy with curettage can be reduced by 90 %. A negative result from the WID®-easy test indicates a high probability of no malignancy. This makes conservative treatment and active monitoring possible for many patients as an alternative to surgical diagnostic testing.